Literature DB >> 24043980

Image-guided percutaneous lipiodol-pingyangmycin suspension injection therapy for sacral chordoma.

Dexiao Huang1, Yong Chen, Qingle Zeng, Renhua Wu, Yanhao Li.   

Abstract

A 74-year-old man presented with a progressively worsening pain in sacrum and was diagnosed to have a sacral chordoma by biopsy in May, 2004. Percutaneous intratumoral injection with lipiodol-pingyangmycin suspension (LPS) was carried out under image guidance and repeated when the pain in sacrum recurred and the tumor increased. During a 6-year follow-up period, three sessions of this treatment were executed. CT imaging and Karnofsky Performance Score were used to evaluate the size of tumor and quality of life, respectively. The patient was free of pain after each procedure and had a high quality of life with a Karnofsky Performance Score above 80 points. The tumor lesion in sacral area was effectively controlled. No complications were observed. Percutaneous intratumoral injection with LPS under image guidance may be an effective and safe alternative for the patients with sacral chordoma.

Entities:  

Keywords:  Lipiodol-pingyangmycin suspension; Percutaneous intratumoral injection; Sacral chordoma

Mesh:

Substances:

Year:  2013        PMID: 24043980      PMCID: PMC3772266          DOI: 10.3348/kjr.2013.14.5.823

Source DB:  PubMed          Journal:  Korean J Radiol        ISSN: 1229-6929            Impact factor:   3.500


  21 in total

1.  Gigantic cavernous hemangioma of the liver treated by intra-arterial embolization with pingyangmycin-lipiodol emulsion: a multi-center study.

Authors:  Qingle Zeng; Yanhao Li; Yong Chen; Yong Ouyang; Xiang He; Heping Zhang
Journal:  Cardiovasc Intervent Radiol       Date:  2004-07-30       Impact factor: 2.740

2.  Radiofrequency ablation in palliative supportive care: early clinical experience.

Authors:  Frédéric Marchal; Laurent Brunaud; Christophe Bazin; Hervé Boccacini; Philippe Henrot; Philippe Troufleau; Ivan Krakowski; Denis Regent
Journal:  Oncol Rep       Date:  2006-02       Impact factor: 3.906

3.  Sacral chordoma: 40-year experience at a major cancer center.

Authors:  J E York; A Kaczaraj; D Abi-Said; G N Fuller; J M Skibber; N A Janjan; Z L Gokaslan
Journal:  Neurosurgery       Date:  1999-01       Impact factor: 4.654

4.  The surgical management of sacrococcygeal chordoma.

Authors:  T Yonemoto; S Tatezaki; T Takenouchi; T Ishii; T Satoh; H Moriya
Journal:  Cancer       Date:  1999-02-15       Impact factor: 6.860

5.  Use of radio-frequency ablation for the palliative treatment of sacral chordoma.

Authors:  Nassar Anis; Nohra Chawki; Khoneisser Antoine
Journal:  AJNR Am J Neuroradiol       Date:  2004-10       Impact factor: 3.825

6.  Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients.

Authors:  P Bergh; L G Kindblom; B Gunterberg; F Remotti; W Ryd; J M Meis-Kindblom
Journal:  Cancer       Date:  2000-05-01       Impact factor: 6.860

7.  Lumbosacral chordoma. Prognostic factors and treatment.

Authors:  E Y Cheng; R A Ozerdemoglu; E E Transfeldt; R C Thompson
Journal:  Spine (Phila Pa 1976)       Date:  1999-08-15       Impact factor: 3.468

8.  Treatment of recurrent chordomas by percutaneous ethanol injection therapy and radiation therapy.

Authors:  M Nakajo; K Ohkubo; Y Fukukura; T Nandate; M Nakajo
Journal:  Acta Radiol       Date:  2006-04       Impact factor: 1.990

9.  Cryoablation of recurrent sacrococcygeal tumors.

Authors:  Anil Nicholas Kurup; David A Woodrum; Jonathan M Morris; Thomas D Atwell; Grant D Schmit; Timothy J Welch; Michael J Yaszemski; Matthew R Callstrom
Journal:  J Vasc Interv Radiol       Date:  2012-08       Impact factor: 3.464

10.  Radical excision of malignant sacral tumors using a modified threadwire saw.

Authors:  Shunzo Osaka; Osamu Kondoh; Yukihiro Yoshida; Junnosuke Ryu
Journal:  J Surg Oncol       Date:  2006-03-15       Impact factor: 3.454

View more
  1 in total

1.  TACE plus percutaneous chemotherapy-lipiodol treatment of unresectable pedunculated hepatocellular carcinoma.

Authors:  Dexiao Huang; Yong Chen; Shuo Chen; Qingle Zeng; Jianbo Zhao; Renhua Wu; Yanhao Li
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.